Article Indicates that Inhibition of PP2A Enhances Immunotherapy Responsewith LIXTE’s Proprietary Compound LB100 PASADENA, Calif., July 09, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced that the medical journal Nature has published findings by a team of physician-scientists that validate LIXTE’s ongoing clinical trials with its proprietary compound LB100 for Ovarian and Colorectal canc ...

PASADENA, CALIF, July 08, 2025 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) (the “Company”), a clinical stage pharmaceutical company, today announced the closing of a registered direct offering with accredited investors for the purchase and sale of approximately $1.5 million of shares of Common Stock (or Pre-Funded Warrants). The offering consisted of the sale of an aggregate of 974,026 shares of Common Stock (or Pre-funded Warrants in lieu thereof). The public offering price per sh ...

PASADENA, CALIF, July 02, 2025 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) (the “Company”), a clinical stage pharmaceutical company, today announced the closing of a private placement with accredited investors for the purchase and sale of approximately $5.0 million of shares of Common Stock (or Pre-Funded Warrants), Series B Convertible Preferred Stock and Common Warrants. The offering was priced at the market under Nasdaq rules. The offering consisted of the sale of an aggregate o ...

Pre-Clinical Study in Collaboration with Netherlands Cancer Institute is in addition to LIXTE's Ongoing Clinical Trials for Ovarian and Colorectal Cancers PASADENA, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced it will conduct a new pre-clinical study in collaboration with Netherlands Cancer Institute (NKI) to test whether "initiated" cells that carry mutations found ...

Core Insights - LIXTE Biotechnology Holdings, Inc. has initiated two new clinical trials in collaboration with MD Anderson and the Netherlands Cancer Institute, focusing on treatments for ovarian and colorectal cancer [1][3] - The company has secured an exclusive patent license agreement with the NIH for LB-100, which aims to enhance cancer immunotherapies [1] - Recent publications in prominent medical journals EMBO and Cancer Discovery support LIXTE's clinical trial program, highlighting the potential of LB-100 in cancer treatment [1][6] Clinical Trials - LIXTE is conducting trials for ovarian cancer at M.D. Anderson Cancer Center and Northwestern University, with support from GSK [2][3] - A colorectal cancer trial is being conducted at the Netherlands Cancer Institute, supported by F. Hoffmann-La Roche [3][6] - The first patient has been dosed in a Phase 1b/2 trial combining LB-100 with GSK's immunotherapy for ovarian clear cell carcinoma [6] Intellectual Property and Research - LIXTE has received a Notice of Allowance from the USPTO for a patent related to the modulation of immune response using LB-100 [6] - Studies published in Cancer Discovery and EMBO indicate that LB-100 can alter cancer cells to enhance their vulnerability to immunotherapy [6] Financial Activities - The company completed a registered direct offering, raising approximately $1,050,000 for working capital and corporate purposes [6]